Statins in conditions other than hypocholesterolemic effects for chronic subdural hematoma therapy, old drug, new tricks?
Metrics: PDF 1240 views | HTML 1420 views | ?
Hai Zou1,*, Xing-Xing Zhu2,*, Ya-Hui Ding1,*, Guo-Bing Zhang3, Yu Geng4 and Dong-Sheng Huang5
1 Department of Cardiology, Zhejiang Provincial People’s Hospital, Hangzhou, China
2 Department of Nephrology, Zhejiang Provincial People’s Hospital, Hangzhou, China
3 Department of Pharmacy, Zhejiang Provincial People’s Hospital, Hangzhou, China
4 Department of Neurology, Zhejiang Provincial People’s Hospital, Hangzhou, China
5 Department of Hepatobiliary Surgery, Zhejiang Provincial People’s Hospital, Hangzhou, China
* Co-first authors: Hai Zou, Xing-Xing Zhu and Ya-Hui Ding
Guo-Bing Zhang, email:
Yu Geng, email:
Dong-Sheng Huang, email:
Keywords: statins; chronic subdural hematoma; endothelial progenitor cells; vascular endothelial growth factor; inflammation
Received: December 10, 2016 Accepted: January 24, 2017 Published: January 04, 2017
Chronic subdural hematoma (CSDH) is one of the most common intracranial hematomas worldwide with a high incidence in the general population. However, the optimum treatment for CSDH is Burr-hole drainage with or without rinse Considering the poor outcomes of CSDH in aged patients, and ambiguous prediction of recurrence in many sides of recurrent CSDHs who have been analyzed, new effective therapies are needed for those CSDHs who are predicated to have poor prognosis for surgery and/or have a higher risk of recurrence. Statins, which is the first-line treatment for patients with high cholesterol and coronary heart disease. However, statins are still not solely limited in the treatment of these diseases. It has been demonstrated that statins could improve CSDH due to its effect of regulation of angiogenesis and inflammation. In this review, in order to provide potential new treatment for CSDH we summarize the recent findings of statins in CSDH in order to try to clarify the mechanisms of this effect.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.